294 related articles for article (PubMed ID: 22498647)
21. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
22. A UPLC-MS/MS assay of the "Pittsburgh cocktail": six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilution.
Stewart NA; Buch SC; Conrads TP; Branch RA
Analyst; 2011 Feb; 136(3):605-12. PubMed ID: 21107456
[TBL] [Abstract][Full Text] [Related]
23. Use of stable isotope labeled probes to facilitate liquid chromatography/mass spectrometry based high-throughput screening of time-dependent CYP inhibitors.
Dasgupta M; Tang W; Caldwell GW; Yan Z
Rapid Commun Mass Spectrom; 2010 Aug; 24(15):2177-85. PubMed ID: 20583325
[TBL] [Abstract][Full Text] [Related]
24. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay.
Turpeinen M; Uusitalo J; Jalonen J; Pelkonen O
Eur J Pharm Sci; 2005 Jan; 24(1):123-32. PubMed ID: 15626586
[TBL] [Abstract][Full Text] [Related]
25. Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds.
Zientek M; Miller H; Smith D; Dunklee MB; Heinle L; Thurston A; Lee C; Hyland R; Fahmi O; Burdette D
J Pharmacol Toxicol Methods; 2008; 58(3):206-14. PubMed ID: 18634893
[TBL] [Abstract][Full Text] [Related]
26. High-throughput, 384-well, LC-MS/MS CYP inhibition assay using automation, cassette-analysis technique, and streamlined data analysis.
Halladay JS; Delarosa EM; Tran D; Wang L; Wong S; Khojasteh SC
Drug Metab Lett; 2011 Aug; 5(3):220-30. PubMed ID: 21867481
[TBL] [Abstract][Full Text] [Related]
27. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.
Yao M; Zhu M; Sinz MW; Zhang H; Humphreys WG; Rodrigues AD; Dai R
J Pharm Biomed Anal; 2007 May; 44(1):211-23. PubMed ID: 17418993
[TBL] [Abstract][Full Text] [Related]
28. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry.
Kim MJ; Kim H; Cha IJ; Park JS; Shon JH; Liu KH; Shin JG
Rapid Commun Mass Spectrom; 2005; 19(18):2651-8. PubMed ID: 16124035
[TBL] [Abstract][Full Text] [Related]
29. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
[TBL] [Abstract][Full Text] [Related]
30. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry.
Testino SA; Patonay G
J Pharm Biomed Anal; 2003 Jan; 30(5):1459-67. PubMed ID: 12467917
[TBL] [Abstract][Full Text] [Related]
31. In vitro assessment of cytochrome P450 inhibition: strategies for increasing LC/MS-based assay throughput using a one-point IC(50) method and multiplexing high-performance liquid chromatography.
Lin T; Pan K; Mordenti J; Pan L
J Pharm Sci; 2007 Sep; 96(9):2485-93. PubMed ID: 17542019
[TBL] [Abstract][Full Text] [Related]
32. Validation of higher-throughput high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes.
Chu I; Favreau L; Soares T; Lin Cc; Nomeir AA
Rapid Commun Mass Spectrom; 2000; 14(4):207-14. PubMed ID: 10669878
[TBL] [Abstract][Full Text] [Related]
33. In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies.
Tolonen A; Petsalo A; Turpeinen M; Uusitalo J; Pelkonen O
J Mass Spectrom; 2007 Jul; 42(7):960-6. PubMed ID: 17565714
[TBL] [Abstract][Full Text] [Related]
34. Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions.
Lee KS; Kim SK
J Appl Toxicol; 2013 Feb; 33(2):100-8. PubMed ID: 21915887
[TBL] [Abstract][Full Text] [Related]
35. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.
Bu HZ; Magis L; Knuth K; Teitelbaum P
Rapid Commun Mass Spectrom; 2001; 15(10):741-8. PubMed ID: 11344532
[TBL] [Abstract][Full Text] [Related]
36. Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes).
Palacharla VRC; Chunduru P; Ajjala DR; Bhyrapuneni G; Nirogi R; Li AP
Drug Metab Dispos; 2019 Oct; 47(10):1032-1039. PubMed ID: 31375472
[TBL] [Abstract][Full Text] [Related]
37. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry.
Dierks EA; Stams KR; Lim HK; Cornelius G; Zhang H; Ball SE
Drug Metab Dispos; 2001 Jan; 29(1):23-9. PubMed ID: 11124225
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous determination of multiple CYP inhibition constants using a cocktail-probe approach.
Zientek M; Youdim K
Methods Mol Biol; 2013; 987():11-23. PubMed ID: 23475664
[TBL] [Abstract][Full Text] [Related]
39. A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS.
Pillai VC; Strom SC; Caritis SN; Venkataramanan R
J Pharm Biomed Anal; 2013 Feb; 74():126-32. PubMed ID: 23245243
[TBL] [Abstract][Full Text] [Related]
40. Absolute protein quantification of clinically relevant cytochrome P450 enzymes and UDP-glucuronosyltransferases by mass spectrometry-based targeted proteomics.
Gröer C; Busch D; Patrzyk M; Beyer K; Busemann A; Heidecke CD; Drozdzik M; Siegmund W; Oswald S
J Pharm Biomed Anal; 2014 Nov; 100():393-401. PubMed ID: 25218440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
